Prednisolone
- Generic Name
- Prednisolone
- Brand Names
- Millipred Dp 6 Day
- Drug Type
- Small Molecule
- Chemical Formula
- C21H28O5
- CAS Number
- 50-24-8
- Unique Ingredient Identifier
- 9PHQ9Y1OLM
- Background
Prednisolone is a glucocorticoid similar to cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.
Prednisolone was granted FDA approval on 21 June 1955.
- Indication
Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Contact Dermatitis, Allergic Skin Reaction, Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonia, Aspiration Pneumonitis, Atopic Dermatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Burns, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Corneal injuries, Corneal ulceration, Crohn's Disease (CD), Cyclitis, Dermatomyositis (DM), Dermatosis of the Ear Canal, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Exacerbation of COPD, Exacerbation of asthma, Eye inflammation caused by Cataract Surgery, Eye inflammation caused by Infection, Fissure;Anal, Herpes Zoster Keratitis, Hot Water Burns (Scalds), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Inflamed External Hemorrhoid, Inflamed Hemorrhoids, Internal, Inflammatory Reaction caused by susceptible Bacterial Infections, Iridocyclitis, Iritis, Itching caused by susceptible Bacterial Infections, Keratitis, Loeffler's syndrome, Lymphoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Otic Eczema, Pemphigus, Perennial Allergic Rhinitis (PAR), Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Posterior Uveitis, Posttraumatic Osteoarthritis, Proctitis, Proteinuria, Pruritus, Pruritus Ani, Psoriatic Arthritis, Pulmonary Tuberculosis (TB), Pure Red Cell Aplasia, Rash, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Seasonal Allergic Rhinitis, Secondary Adrenal Insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Asthma, Sjogren's Syndrome (SS), Stevens-Johnson Syndrome, Superficial punctate keratitis, Synovitis, Systemic Lupus Erythematosus, Transplanted Organ Rejection, Trichinosis, Tuberculosis (TB), Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Rheumatic heart disease, unspecified, Acute Tenosynovitis, Anal eczema, Bacterial skin infections, Exfoliative erythroderma, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Primary adrenocoritical insufficiency, Severe Psoriasis, Severe Seborrhoeic dermatitis, Severe alcoholic liver disease, Steroid-responsive inflammation of the eye, Subacute Bursitis, Susceptible Bacterial Infections, Symptomatic Sarcoidosis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- -
Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism
- Conditions
- Interventions
- First Posted Date
- 2017-10-05
- Last Posted Date
- 2017-10-05
- Lead Sponsor
- Clinical Research Centre, Malaysia
- Target Recruit Count
- 135
- Registration Number
- NCT03303053
- Locations
- 🇲🇾
Hospital Ampang, Ampang, Selangor, Malaysia
🇲🇾Hospital Putrajaya, Putrajaya, Wilayah Persekutuan, Malaysia
🇲🇾Hospital Queen Elizabeth 2, Kota Kinabalu, Sabah, Malaysia
Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921
- Conditions
- Interventions
- First Posted Date
- 2017-09-29
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 100
- Registration Number
- NCT03298061
- Locations
- 🇬🇧
GSK Investigational Site, Leicester, United Kingdom
ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2022-09-28
- Target Recruit Count
- 60
- Registration Number
- NCT03286634
- Locations
- 🇯🇵
Kagoshima University Hospital, Kagoshima, Japan
🇲🇾University of Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾Subang Jaya Medical Centre, Subang Jaya, Malaysia
Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2017-07-07
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 71
- Registration Number
- NCT03210688
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇩🇰Regional Hospital Viborg, Viborg, Denmark
Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
- Conditions
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 650
- Registration Number
- NCT03206671
- Locations
- 🇫🇮
Turku University Hospital, Paediatric and Adolescent Haematology and Oncology, Turku, Finland
🇨🇭Universitäts-Kinderspital, Pädiatrische Onkologie, Zürich, Switzerland
🇨🇭Kinderspital Pädiatrische Hämatologie/ Onkologie, Luzern, Switzerland
A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study)
- Conditions
- Interventions
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03200561
- Locations
- 🇨🇳
China Medical University Hospital, Taichung, Taiwan
A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 120
- Registration Number
- NCT03198013
- Locations
- 🇦🇺
Local Institution, Melbourne, Victoria, Australia
Sirolimus Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma
- Conditions
- Interventions
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03188068
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA
- Conditions
- Interventions
- First Posted Date
- 2017-06-01
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 136
- Registration Number
- NCT03172325
- Locations
- 🇮🇷
Alzahra Hospital, Isfahan, Iran, Islamic Republic of
🇮🇷Imam Reza Hospital (501 Artesh), Tehran, Iran, Islamic Republic of
🇮🇷Noor Medical Complex, Tabriz, Iran, Islamic Republic of
Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate
- Conditions
- Interventions
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2022-10-26
- Target Recruit Count
- 123
- Registration Number
- NCT03156452
- Locations
- 🇬🇧
University Hospital Bristol NHS Foundation Trust, Bristol, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.